MPL-009
Phase 2Small molecule
MPL-009 is one of 25 small molecule programs targeting Pediatric. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
31 competitors in Pediatric
#DrugCompanyPhaseTrials
1Oxycontin
PProtega
Approved
Periactin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Siliq
BBausch Health Americas, Inc.
Approved
Blincyto
AmgenPhase 3
Venclexta
AbbViePhase 3
Sprycel
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Luye
Ascentage Pharma Group Inc.Phase 3
Homoharringtonine
Ascentage Pharma Group Inc.Phase 3
Fycompa
CCatalyst Biosciences
Phase 2
Jemperli
GGlaxo Dba Glaxosmithkline
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MPL-009. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Manitoba